Home › Companies › Arbutus Biopharma Corporation › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Arbutus Biopharma Corporation’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 26, 2026: 8 items on Arbutus Biopharma Corporation’s Form 8-K, filed May 27, 2026: 3 approved · 5 passed (calculated).
Notable dissent: 1 director (13.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Two Seas Capital LP (13F, 4.1%, as of September 30, 2026) · Rubric Capital (13F, 1.7%, as of September 30, 2026)
Explore Arbutus Biopharma Corporation in the interactive database Compare manager voting policies
These tallies are Arbutus Biopharma Corporation’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Lindsay Androski, JD, MBA, CFA | 136,780,089 | -- | -- | 9,693,538 | 22,829,831 | 93% | Passed (calculated) | — |
| Elect Director: Robert Alan Beardsley | 138,456,756 | -- | -- | 8,016,871 | 22,829,831 | 95% | Passed (calculated) | — |
| Elect Director: Joseph Bishop | 137,372,240 | -- | -- | 9,101,387 | 22,829,831 | 94% | Passed (calculated) | — |
| Elect Director: Matthew Gline | 126,670,273 | -- | -- | 19,803,354 | 22,829,831 | 86% | Passed (calculated) | — |
| Elect Director: Roger Sawhney, MD | 139,299,405 | -- | -- | 7,174,222 | 22,829,831 | 95% | Passed (calculated) | — |
| 2. Approved the adoption of the 2026 Plan | 138,877,189 | 7,408,185 | 188,253 | -- | 22,829,831 | 95% | Approved | — |
| 3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular | 137,629,207 | 8,331,760 | 512,660 | -- | 22,829,831 | 94% | Approved | — |
| 4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 164,372,596 | 2,123,916 | 2,806,946 | -- | -- | 99% | Approved | — |
Source: Arbutus Biopharma Corporation, Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
147 asset managers disclosed a vote on at least one Arbutus Biopharma Corporation item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Prior year: 93.8% for (May 21, 2025 meeting) unchanged
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop
Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Joseph Bishop”): 137,372,240 for, 9,101,387 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 27,898,121 for, 275,804 withheld, 28 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,987,215 | 0 | 28 | 6,273 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 4,907,707 | 0 | 0 | 0 | For |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,756,377 | 0 | 0 | 0 | For |
| Equitable | 1,651,258 | 0 | 0 | 0 | For |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 256,883 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 248,061 | 0 | 0 | 0 | For |
| Invesco | 148,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 70,920 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 51,981 | 0 | 0 | 0 | For |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 40,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,901 | 0 | 0 | 0 | For |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Prior year: 95.1% for (May 21, 2025 meeting) ▼ 1.8 pts
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Lindsay Androski, JD, MBA, CFA
Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Lindsay Androski, JD, MBA, CFA”): 136,780,089 for, 9,693,538 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 28,161,275 for, 12,648 withheld, 30 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,993,486 | 0 | 30 | 0 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 4,907,707 | 0 | 0 | 0 | For |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,756,377 | 0 | 0 | 0 | For |
| Equitable | 1,651,258 | 0 | 0 | 0 | For |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 256,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 248,061 | 0 | 0 | 0 | For |
| Invesco | 148,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 70,920 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 51,981 | 0 | 0 | 0 | For |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 40,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,901 | 0 | 0 | 0 | For |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Prior year: 94.3% for (May 21, 2025 meeting) ▼ 7.8 pts
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline
Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Matthew Gline”): 126,670,273 for, 19,803,354 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 22,059,662 for, 925,593 withheld, 5,188,698 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,987,214 | 0 | 29 | 6,273 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 4,907,707 | 0 | Abstain |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,693,046 | 0 | 0 | 63,331 | For |
| Equitable | 1,404,832 | 0 | 0 | 246,426 | Mixed |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 256,883 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 248,061 | 0 | Abstain |
| Invesco | 0 | 0 | 0 | 148,531 | Withhold |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 70,920 | Withhold |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 0 | 0 | 0 | 51,981 | Withhold |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 40,001 | Withhold |
| Bridge Builder Trust | 0 | 0 | 32,901 | 0 | Abstain |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Prior year: 95.9% for (May 21, 2025 meeting) ▼ 1.4 pts
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Robert Alan Beardsley
Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Robert Alan Beardsley”): 138,456,756 for, 8,016,871 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 28,173,929 for, 24 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,993,492 | 0 | 24 | 0 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 4,907,707 | 0 | 0 | 0 | For |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,756,377 | 0 | 0 | 0 | For |
| Equitable | 1,651,258 | 0 | 0 | 0 | For |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 256,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 248,061 | 0 | 0 | 0 | For |
| Invesco | 148,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 70,920 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 51,981 | 0 | 0 | 0 | For |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 40,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,901 | 0 | 0 | 0 | For |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Roger Sawhney, MD
Arbutus Biopharma Corporation’s own tally for this item (“Elect Director: Roger Sawhney, MD”): 139,299,405 for, 7,174,222 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 28,173,931 for, 22 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,993,494 | 0 | 22 | 0 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 4,907,707 | 0 | 0 | 0 | For |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,756,377 | 0 | 0 | 0 | For |
| Equitable | 1,651,258 | 0 | 0 | 0 | For |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 256,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 248,061 | 0 | 0 | 0 | For |
| Invesco | 148,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 70,920 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 51,981 | 0 | 0 | 0 | For |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 40,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,901 | 0 | 0 | 0 | For |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: TO APPROVE THE ADOPTION OF THE ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN;
Arbutus Biopharma Corporation’s own tally for this item (“2. Approved the adoption of the 2026 Plan”): 138,877,189 for, 7,408,185 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) approved the adoption of the 2026 Plan”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,980,229 | 13,287 | 0 | 0 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 4,907,707 | 0 | 0 | 0 | For |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,756,377 | 0 | 0 | 0 | For |
| Equitable | 1,651,258 | 0 | 0 | 0 | For |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 256,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 248,061 | 0 | 0 | 0 | For |
| Invesco | 0 | 148,531 | 0 | 0 | Against |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 70,920 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 51,981 | 0 | 0 | 0 | For |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 40,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,901 | 0 | 0 | 0 | For |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Fund voting reports, all 37 managers: 28,011,325 for, 162,628 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deltroit Asset Management (UK) LLP | 800,000 | 0 | 0 | 0 | For |
| Rangeley Capital, LLC | 353,501 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 1,153,501 for.
Combines 4 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 94.6% for (May 21, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and
Arbutus Biopharma Corporation’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”): 137,629,207 for, 8,331,760 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,993,489 | 25 | 1 | 0 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 4,907,707 | 0 | 0 | 0 | For |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,756,377 | 0 | 0 | 0 | For |
| Equitable | 1,651,258 | 0 | 0 | 0 | For |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 256,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 248,061 | 0 | 0 | 0 | For |
| Invesco | 0 | 148,531 | 0 | 0 | Against |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 70,920 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 51,981 | 0 | 0 | 0 | For |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 40,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,901 | 0 | 0 | 0 | For |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Fund voting reports, all 37 managers: 28,025,395 for, 148,556 against, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Morgan Stanley | 25,251,082 | 0 | 0 | 0 | For |
| Two Seas Capital LP | 14,717,397 | 0 | 0 | 0 | For |
| State Street | 5,661,682 | 23,979 | 0 | 0 | For |
| BlackRock | 4,883,883 | 33,074 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 2,370,471 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,117,957 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 1,627,678 | 0 | 0 | 0 | For |
| Charles Schwab | 1,400,489 | 0 | 0 | 0 | For |
| Rubric Capital Management LP | 1,265,390 | 0 | 0 | 0 | For |
| Vanguard | 1,242,762 | 0 | 0 | 0 | For |
| Northern Trust | 880,731 | 16,948 | 0 | 0 | For |
| Deltroit Asset Management (UK) LLP | 800,000 | 0 | 0 | 0 | For |
| UBS | 0 | 741,177 | 0 | 0 | Against |
| Rangeley Capital, LLC | 353,501 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 301,741 | 0 | 0 | 0 | For |
| Wellington | 290,344 | 0 | 0 | 0 | For |
| Nuveen | 259,017 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 256,841 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 216,239 | 0 | 0 | 0 | For |
| Western Standard LLC | 215,038 | 0 | 0 | 0 | For |
| T. Rowe Price | 186,890 | 0 | 0 | 0 | For |
| Fidelity | 140,917 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 140,384 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 108,486 | 30,087 | 0 | 0 | Mixed |
| AllianceBernstein | 127,340 | 0 | 0 | 0 | For |
Institutional-manager reports, all 122 managers: 66,098,610 for, 1,011,414 against, 700 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: TO APPROVE THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Arbutus Biopharma Corporation’s own tally for this item (“4. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 164,372,596 for, 2,123,916 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(4) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 37 asset managers below reported 28,173,946 for, 3 against, 5 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,993,509 | 3 | 5 | 0 | For |
| Morgan Stanley | 6,182,656 | 0 | 0 | 0 | For |
| BlackRock | 4,907,707 | 0 | 0 | 0 | For |
| State Street | 2,680,508 | 0 | 0 | 0 | For |
| Fidelity | 1,756,377 | 0 | 0 | 0 | For |
| Equitable | 1,651,258 | 0 | 0 | 0 | For |
| Charles Schwab | 1,399,892 | 0 | 0 | 0 | For |
| TIAA | 256,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 248,061 | 0 | 0 | 0 | For |
| Invesco | 148,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 102,200 | 0 | 0 | 0 | For |
| Goldman Sachs | 99,139 | 0 | 0 | 0 | For |
| ProShares | 86,900 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,331 | 0 | 0 | 0 | For |
| Northern Trust | 75,298 | 0 | 0 | 0 | For |
| Global X | 70,920 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 57,895 | 0 | 0 | 0 | For |
| Pacific Life | 51,981 | 0 | 0 | 0 | For |
| Brighthouse | 48,336 | 0 | 0 | 0 | For |
| John Hancock | 42,237 | 0 | 0 | 0 | For |
| Nationwide | 40,001 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,901 | 0 | 0 | 0 | For |
| Voya | 28,676 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 28,437 | 0 | 0 | 0 | For |
| DWS | 21,573 | 0 | 0 | 0 | For |
Showing the 25 largest of 37 asset managers. All 37 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 197,537,710 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.05% |
| 2 | Morgan Stanley | 3.13% |
| 3 | BlackRock | 2.48% |
| 4 | State Street | 1.36% |
| 5 | Fidelity | 0.89% |
| 6 | Equitable | 0.84% |
| 7 | Charles Schwab | 0.71% |
| 8 | TIAA | 0.13% |
| 9 | QUANTITATIVE MASTER SERIES LLC | 0.13% |
| 10 | Invesco | 0.08% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Morgan Stanley | 12.78% |
| 2 | Two Seas Capital LP | 7.45% |
| 3 | State Street | 2.88% |
| 4 | BlackRock | 2.49% |
| 5 | Legal & General Investment Management Ltd | 1.20% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.07% |
| 7 | ADAR1 Capital Management, LLC | 0.82% |
| 8 | Charles Schwab | 0.71% |
| 9 | Rubric Capital Management LP | 0.64% |
| 10 | Vanguard | 0.63% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Matthew Gline | 38,847,462 | — | Proxy statement (DEF 14A), table as of March 30, 2026 |
| Roivant Sciences Ltd. | 38,847,462 | — | Proxy statement (DEF 14A), table as of March 30, 2026 |
| Morgan Stanley | 26,702,776 | — | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with Morgan Stanley | 25,910,337 | — | Proxy statement (DEF 14A), table as of March 30, 2026 |
| Two Seas Capital LP | 18,557,543 | — | Schedule 13G, filed May 15, 2026 |
| Entities affiliated with Whitefort Capital Management, LP | 14,930,885 | — | Proxy statement (DEF 14A), table as of March 30, 2026 |
| BlackRock | 12,966,946 | — | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with Two Seas Capital LP | 12,589,158 | — | Proxy statement (DEF 14A), table as of March 30, 2026 |
| Entities affiliated with Blackrock, Inc. | 10,390,300 | — | Proxy statement (DEF 14A), table as of March 30, 2026 |
| Vanguard Group | 9,242,437 | — | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 197,537,710 shares outstanding, as reported by Arbutus Biopharma Corporation on its Form 10-Q dated May 11, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Arbutus Biopharma Corporation's shareholder meeting held May 26, 2026, in the 2025-2026 proxy season, 147 asset managers reported votes on at least one of its 8 ballot items in their SEC Form N-PX filings, covering 1,266 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — Arbutus Biopharma Corporation's filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Arbutus Biopharma Corporation's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 27, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arbutus Biopharma Corporation’s 10-Q dated May 11, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Arbutus Biopharma Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Arbutus Biopharma (ABUS) 2026 Annual & Special Meeting: Vote Results”, https://proxyvotesnow.com/company/arbutus-biopharma-corp/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.